Researchers Discover Key Molecule to Improve Cystic Fibrosis Treatment
Long-term goals
Brocherio further discusses the impact of the team's work, "by using cells collected from patients, we think that it will be possible to test and predict the efficacy of treatments such as Kalydeco and Orkambi, on cells collected from the patient, in the presence of the bacteria taken from the same patient. We'll also evaluate the ability of the treatments to repair damage and lung tissue. And lastly, we'll work on identifying the most effective molecules, such as bacterial quorum-sensing inhibitors, that can counteract the harmful effect of infections. The ultimate goal is to improve treatments for patients and, by doing so, extend their life."
